Dr. Thomas Carpenter, M.D., talks about the recent FDA approval (April 2018) of Crysvita® (burosumab-twza) for the treatment of X-Linked Hypophosphatemia (XLH), a rare skeletal disorder, and what that means to the XLH community and the daily struggles of patients living with XLH.
Guest Bio: Dr. Carpenter has maintained a career-long involvement in metabolic bone diseases in children. He currently directs the Yale Center for X-linked Hypophosphatemia (XLH) and the Physiology Core of the Yale Core Center for Musculoskeletal Diseases. His research interests center on the pathophysiology and the development of therapy for XLH, the most common inherited form of rickets. He also has a major interest in the metabolism and function of vitamin D, and disorders related to vitamin D in children. He served as director of the Yale Pediatric Endocrinology Fellowship Training Program for over 20 years, and is Clinical Director of the Yale’s Pediatric Endocrinology Section.